Siga Technologies (SIGA) Share-based Compensation (2010 - 2025)
Siga Technologies' (SIGA) quarterly Share-based Compensation came in at $774104.0 in Q3 2025, down 4.87% on a YoY basis from $813774.0 in Q3 2024, and down 37.29% quarter-over-quarter from $1.2 million in Q2 2025.
Analysis
Siga Technologies (SIGA) Share-based Compensation (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Share-based Compensation for 16 consecutive years, with $774104.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Share-based Compensation fell 4.87% year-over-year to $774104.0; the trailing twelve-month figure through Sep 2025 stood at $3.7 million (up 8.53% YoY), and the FY2024 full-year result was $3.6 million, up 73.34% from the prior year.
- Share-based Compensation slipped to $774104.0 in Q3 2025 per SIGA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q2 2025 and bottomed at $243503.0 in Q3 2021.
- Historically, Share-based Compensation has averaged $618471.8 across 5 years, with a median of $510007.0 in 2023.
- The sharpest annual moves came in 2021 and 2024: Share-based Compensation sank 36.06% in 2021, then soared 176.47% in 2024.
- Over 5 years, Share-based Compensation stood at $342680.0 in 2021, then surged by 106.35% to $707107.0 in 2022, then retreated by 27.87% to $510007.0 in 2023, then surged by 49.82% to $764070.0 in 2024, then rose by 1.31% to $774104.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $774104.0, $1.2 million, and $902280.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 277.20 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 774,104.00 |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 902,280.00 |
| Dec 31, 2024 | 764,070.00 |
| Sep 30, 2024 | 813,774.00 |
| Jun 30, 2024 | 932,287.00 |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 510,007.00 |
| Sep 30, 2023 | 459,823.00 |
| Jun 30, 2023 | 721,440.00 |
| Mar 31, 2023 | 408,730.00 |
| Dec 31, 2022 | 707,107.00 |
| Sep 30, 2022 | 328,685.00 |
| Jun 30, 2022 | 395,454.00 |
| Mar 31, 2022 | 368,754.00 |
| Dec 31, 2021 | 342,680.00 |
| Sep 30, 2021 | 243,503.00 |
| Jun 30, 2021 | 467,405.00 |
| Mar 31, 2021 | 246,412.00 |
| Dec 31, 2020 | 436,628.00 |